Bingjie Wang

Dr. Bingjie Wang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in International Immunopharmacology
Verified
Journal Article
Open access
JZJinye Zhu
Jinye Zhu
QWQian Wang
Qian Wang
YLYongjia Liu
Yongjia Liu
YDYujun Dong
Yujun Dong
ZLZeyin Liang
Zeyin Liang
YLYuan Li
Yuan Li
Donor-specific anti-HLA antibody (DSA) is a significant obstacle to successful haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and is associated with poor engraftment rates. DSA strongly positive patients with a mean fluorescence intensity (MFI) over 5000 have a primary poor graft function (PGF) rate of over 60%. Currently, there is no consensus on the desensitization of DSA, and existing strategies are complex and have limited effectiveness. To address this issue, we conducted a retrospective study on 19 patients with strongly positive DSA (MFI over 5000) who underwent haplo-HSCT and were treated with intravenous immunoglobulin (IVIg)-based therapy. We also included 38 baseline-matched patients with DSA-negative as controls. Our findings revealed that the cumulative incidence of engraftment, PGF, graft-versus-host disease (GVHD), virus infection, overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) in the DSA strongly positive group after desensitization were comparable to those in the DSA negative group (P > 0.05). Our multivariable analysis showed that disease remission was a protective factor against PGF (P = 0.005, OR = 0.019, 95% CI 0.001-0.312). Subgroup analysis revealed that the desensitization efficacy was equal regardless of DSA type against HLA-I or II, and MFI value over 5000 or not. In conclusion, we propose a simple and effective DSA desensitization strategy based on immunoglobulin to ensure successful engraftment and improve patient prognosis.

27 June 2023 in Transplantation Proceedings
Verified
Journal Article
Closed access
BWBingjie Wang
Bingjie Wang
YYYue Yin
Yue Yin
YLYuan Li
Yuan Li
ZLZeyin Liang
Zeyin Liang
WLWei Liu
Wei Liu
HRHanyun Ren
Hanyun Ren


17 April 2026 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
BWBingjie Wang
Bingjie Wang
SXShuanglian Xie
Shuanglian Xie
WXWeiwei Xie
Weiwei Xie
JZJialin Zhu
Jialin Zhu
BTBo Tang
Bo Tang
YDYujun Dong
Yujun Dong

28 April 2026 in Cancer Medicine
Verified
Journal Article
Open access
XZXian Zhang
Xian Zhang
BWBingjie Wang
Bingjie Wang
YDYujun Dong
Yujun Dong
QWQingya Wang
Qingya Wang
QWQian Wang
Qian Wang
YLYuan Li
Yuan Li
Background: GATA binding protein 2 (GATA2) plays a crucial role in the differentiation, proliferation, and maintenance of hematopoietic stem cells (HSCs). GATA2 mutations have been identified in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), but the impact of somatic GATA2 mutations on prognosis remains controversial, especially on patients who undergo allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Objectives: The aim of this retrospective case–control study was to explore the prognostic significance of somatic GATA2 mutations in MDS/AML patients who underwent allo‐HSCT. Study Design: Propensity score matching (PSM) analysis was used to match patients with wild‐type GATA2 as the control group (ratio 1:3). A total of 14 patients with somatic GATA2 mutations and 39 patients with wild‐type GATA2 were enrolled. Results: The baseline characteristics were comparable between the two groups. However, patients with GATA2 mutations had a higher frequency of WT1 mutations and relapse rate ( p = 0.036 and p = 0.008, respectively). Compared to patients with wild‐type GATA2, patients with GATA2 mutations had shorter progression‐free survival (PFS) and overall survival (OS), and post‐transplant PFS ( p < 0.001, p = 0.030, and p = 0.004, respectively). Subgroup analysis showed that the PFS, OS, post‐transplant PFS, and OS of patients with GATA2 non‐zinc finger domain 1 (non‐ZF1) mutations ( p < 0.001, p = 0.004, p < 0.001, and p = 0.049, respectively), but not those of patients with somatic GATA2 ZF1 mutations, were shorter than that of patients with wild‐type GATA2. Moreover, somatic GATA2 mutations and WBC count ≥ 20.86 × 10 9 /L were independent adverse prognostic factors for PFS ( p = 0.005 and p = 0.020, respectively). Relapse before transplantation was an independent adverse prognostic factor for OS ( p = 0.009). Conclusions: Our preliminary study revealed that somatic GATA2 mutations, especially non‐ZF1 mutations, may be associated with unfavorable outcomes in patients with MDS/AML, even for patients who underwent allo‐HSCT.

3 April 2020 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
BWBingjie Wang
Bingjie Wang
ZLZeyin Liang
Zeyin Liang
WLWei Liu
Wei Liu
YSYuhua Sun
Yuhua Sun
XCXi’nAn Cen
Xi’nAn Cen
HRHanyun Ren
Hanyun Ren